The deal brings an experimental cholesterol treatment, inclisiran, into a stable of Novartis products that includes the heart-failure medicine Entresto.
LONDON: Novartis AG agreed to buy Medicines Co. for about $6.8 billion, snapping up a promising cholesterol drug and adding to a string of recent acquisitions for Chief Executive Officer Vas Narasimhan.
Medicines Co. shareholders will get $85 a share, Basel, Switzerland-based Novartis said in a statement on Sunday. That’s a 45% premium to the closing price on Nov. 18, before Bloomberg reported the two companies were in talks. The transaction value reaches $9.7 billion on a fully diluted basis that includes outstanding stock options and convertible debt, Novartis said.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
